Epidiolex

Marinus Pharmaceuticals

This pharmaceutical company produces ganaxolone, an oral suspension treatment for seizures in adult and paediatric patients with rare genetic epilepsy disorders.

EpilepsyGTx

This company develops precision gene therapies for patients with focal refractory epilepsy to provide seizure freedom.

Sonas pHARMA

This company develops precision endocannabinoid medicines to treat epilepsy and metabolic diseases for patients with unmet medical needs.

Neurosciences

This company develops precision sodium channel therapeutics to treat patients with neurological conditions such as genetic epilepsy and chronic neuropathic pain.

GenEp

The company develops therapies targeting ion channel mutations to treat rare genetic and treatment-resistant epilepsies for patients with unmet medical needs.

Encoded Therapeutics

This biotechnology company develops precision genetic medicines for patients with severe neurological disorders, including Dravet syndrome.

IAMA Therapeutics

This company develops small molecule drugs to treat neurodevelopmental and central nervous system disorders for patients with autism and epilepsy.

Stoke Therapeutics

This biotechnology company develops antisense oligonucleotide medicines to treat severe genetic diseases by restoring protein expression for patients with conditions such as Dravet syndrome.